Hahn May Not Run Into Questions About Industry Ties Like His Predecessors
Nominee for US FDA commissioner has remained largely focused on academic work and private practice, receiving only a few payments from pharma and device companies.
You may also be interested in...
Flagship, the investor behind COVID-19 success story Moderna, has raised a huge fund that will be used to create and develop its own companies before spinning them off.
Stephen Hahn will have over 100 stocks to divest upon becoming FDA commissioner.
Stephen Hahn will go before the Senate health committee less than three weeks after being nominated. Pink Sheet's historical charts illustrate how a long wait and a quick hearing could mean a rapid confirmation.